Metabolic dysfunction-associated liver disease predicts incident liver fibrosis in people with HIV mono-infection: A cohort study.

ABSTRACT:

Introduction

Metabolic dysfunction-associated liver disease (MASLD) might progress to cirrhosis. We aimed to evaluate the association of MASLD with the risk of developing clinically significant fibrosis (CSF) in people living with HIV (PLWH).

Methods

PLWH have been followed up since 2015 in the PROSPEC-HIV cohort (NCT02542020) with questionnaires, blood samples, and transient elastography (TE) on the same day. Participants with viral hepatitis, who were c-ART naïve, those with CSF at baseline or unreliable TE examinations and who lost follow-up were excluded. Liver steatosis and fibrosis were assessed by TE-Controlled Attenuation Parameter (CAP) and TE-liver stiffness measurement (LSM), respectively. MASLD was defined as the presence of steatosis (CAP ≥263 dB/m) at baseline

SUBMITTER: Fittipaldi J 

PROVIDER: S-EPMC12497932 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature